Published in Nat Commun on December 15, 2014
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell (2016) 2.39
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell (2015) 2.12
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (2016) 1.95
Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. J Pathol (2016) 1.45
Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res (2015) 1.12
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat Commun (2015) 1.10
MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun (2015) 1.01
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. Clin Cancer Res (2016) 1.00
Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget (2015) 0.91
A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat Med (2016) 0.91
miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. Oncotarget (2015) 0.91
Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling. Theranostics (2016) 0.87
Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature (2017) 0.87
The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Biochem Pharmacol (2016) 0.86
Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. Oncotarget (2016) 0.85
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature (2017) 0.83
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. Front Cell Dev Biol (2016) 0.83
ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. EMBO Mol Med (2016) 0.83
Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Rep (2015) 0.81
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol Med (2017) 0.80
Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells. Oncogene (2016) 0.79
Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools. Oncogene (2016) 0.79
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Oncotarget (2016) 0.79
BMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistance. Genes Dev (2015) 0.79
The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma. Oncotarget (2016) 0.78
Melanoma: oncogenic drivers and the immune system. Ann Transl Med (2015) 0.78
miR-579-3p controls melanoma progression and resistance to target therapy. Proc Natl Acad Sci U S A (2016) 0.78
FOXD3 Promotes PAX3 Expression in Melanoma Cells. J Cell Biochem (2015) 0.78
A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib. EBioMedicine (2016) 0.78
The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Lab Invest (2017) 0.78
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. Genes Dev (2017) 0.77
Giving AXL the axe: targeting AXL in human malignancy. Br J Cancer (2017) 0.77
BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Rep (2016) 0.77
Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol (2017) 0.77
The UPs and DOWNs of MITF in melanoma resistance. Pigment Cell Melanoma Res (2014) 0.76
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discov (2016) 0.76
Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma. PLoS One (2015) 0.76
NFATc2 is an intrinsic regulator of melanoma dedifferentiation. Oncogene (2015) 0.76
ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget (2015) 0.76
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget (2016) 0.76
The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors. Pigment Cell Melanoma Res (2015) 0.76
Metabolic rewiring in melanoma. Oncogene (2016) 0.76
MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma. Oncotarget (2016) 0.75
Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. Mol Syst Biol (2017) 0.75
The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels. PLoS One (2015) 0.75
Targeting MITF in the tolerance-phase. Oncotarget (2016) 0.75
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer (2017) 0.75
The Receptor Tyrosine Kinase AXL in Cancer Progression. Cancers (Basel) (2016) 0.75
Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma. Front Oncol (2016) 0.75
Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance. Clin Cancer Res (2016) 0.75
Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals. Oncogene (2016) 0.75
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies. Curr Oncol Rep (2017) 0.75
Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of ATG5. Autophagy (2016) 0.75
A stochastic model for immunotherapy of cancer. Sci Rep (2016) 0.75
Chemotherapy Resistance Mechanisms in Advanced Skin Cancer. Oncol Rev (2017) 0.75
Focus on cutaneous and uveal melanoma specificities. Genes Dev (2017) 0.75
Cancer: Tumours addicted to drugs are vulnerable. Nature (2017) 0.75
BRAF(V600) inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells. Proc Natl Acad Sci U S A (2017) 0.75
Intratumor and Intertumor Heterogeneity in Melanoma. Transl Oncol (2017) 0.75
Phenotypic diversity drives paracrine drug tolerance. EMBO Mol Med (2017) 0.75
A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF. Nat Genet (2017) 0.75
The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation. Oncogene (2017) 0.75
TopHat: discovering splice junctions with RNA-Seq. Bioinformatics (2009) 81.13
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Differential expression analysis for sequence count data. Genome Biol (2010) 64.56
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol (2013) 32.42
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol (2012) 14.01
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Improving RNA-Seq expression estimates by correcting for fragment bias. Genome Biol (2011) 10.63
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell (1993) 5.00
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov (2013) 4.39
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature (2014) 3.80
Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet (2004) 3.78
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res (2008) 3.66
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A (2009) 3.29
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev (2006) 2.87
Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. Hum Mol Genet (2000) 2.63
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov (2014) 2.51
Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature (2005) 2.44
Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res (2010) 2.43
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov (2013) 2.43
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 2.12
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol (2011) 2.09
Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia (2005) 2.04
AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res (2008) 2.01
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst (2012) 2.01
MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol (2004) 1.89
Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene (2011) 1.83
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. Proc Natl Acad Sci U S A (2009) 1.49
Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res (2004) 1.32
The tyrosinase enhancer is activated by Sox10 and Mitf in mouse melanocytes. Pigment Cell Res (2007) 1.18
Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ (2014) 1.05
Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Oncogene (2011) 1.05
Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. Oncotarget (2013) 0.92
Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines. Melanoma Res (2013) 0.83